Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

被引：1

作者：

Patel, Krish ^{[1
]}

Vose, Julie M. ^{[2
]}

Nasta, Sunita D. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Maddocks, Kami J. ^{[6
]}

Woyach, Jennifer A. ^{[6
]}

Shah, Nirav N. ^{[7
]}

Fakhri, Bita ^{[8
]}

Tessoulin, Benoit ^{[9
]}

Ma, Shuo ^{[10
]}

Jagadeesh, Deepa ^{[11
]}

Lech-Maranda, Ewa ^{[12
]}

Coombs, Catherine C. ^{[13
]}

Patel, Manish ^{[14
]}

Rhodes, Joanna M. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Hoffmann, Marc S. ^{[17
]}

Cheah, Chan Y. ^{[18
,19
]}

Munir, Talha ^{[20
]}

Lewis, David ^{[21
]}

Scarfo, Lydia ^{[22
]}

Eyre, Toby A. ^{[23
]}

Alencar, Alvaro J. ^{[24
]}

Cohen, Jonathon B. ^{[25
]}

Zelenetz, Andrew D. ^{[26
]}

Tsai, Donald E. ^{[27
]}

Li, Mei ^{[28
]}

Bian, Faith ^{[28
]}

Abada, Paolo ^{[27
]}

Zinzani, Pier Luigi ^{[29
]}

机构：

[1] Swedish Canc Inst, Seattle, WA USA

[2] Univ Nebraska Med Ctr, Omaha, NE USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Chron Lymphocyt Leukemia Ctr, Div Med Oncol, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[8] Stanford Univ, Sch Med, Stanford, CA USA

[9] Univ Hosp, Dept Hematol, Nantes, France

[10] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA

[11] Inst Hematol & Transfus Med, Warsaw, Poland

[12] Univ Calif Irvine, Irvine, CA USA

[13] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[14] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[15] Fred Hutchinson Canc Ctr, Seattle, WA USA

[16] Univ Kansas, Ctr Canc, Kansas City, KS USA

[17] Linear Clin Res, Nedlands, WA, Australia

[18] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[19] St James Univ Hosp, Dept Haematol, Leeds, W Yorkshire, England

[20] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England

[21] Univ Vita Salute San Raffaele, Milan, Italy

[22] IRCCS San Raffaele Sci Inst, Milan, Italy

[23] Oxford Univ Hosp NHS Trust, Dept Clin Haematol, Old Rd, Oxford, England

[24] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami Beach, FL USA

[25] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[26] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[27] Loxo Lilly, Indianapolis, IN USA

[28] Eli Lilly & Co, Indianapolis, IN 46285 USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180048

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：9

共 50 条

[21] Pirtobrutinib, a Next-Generation, Highly Selective, Noncovalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 10 - 11
[22] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 10 - 11
[23] LOXO-305, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results From the Phase 1/2 BRUIN Study
Wang, Michael
Shah, Nirav N.
Alencar, Alvaro J.
Gerson, James N.
Patel, Manish R.
Fakhri, Bita
Jurczak, Wojciech
Tan, Xuan Ni
Lewis, Katharine L.
Fenske, Timothy S.
Coombs, Catherine C.
Flinn, Ian W.
Lewis, David John
Le Gouill, Steven
Palomba, M. Lia
Woyach, Jennifer A.
Pagel, John M.
Lamanna, Nicole
Cohen, Jonathon B.
Barve, Minal
Ghia, Paolo
Eyre, Toby A.
Yin, Ming
Nair, Binoj
Tsai, Donald
Ku, Nora C.
Mato, Anthony
Cheah, Chan Yoon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 11 - 12
[24] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Gerson, James N.
Flinn, Ian W.
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna M.
Patel, Krish
Woyach, Jennifer A.
Lamanna, Nicole
Wang, Yucai
Tam, Constantine S.
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew D.
Jain, Preetesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo B.
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BLOOD, 2022, 140 : 9368 - 9372
[25] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
Lewis, David John
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutzu, Koji
Gerson, James N.
Flinn, Ian
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna
Patel, Krish
Woyach, Jennifer
Lamanna, Nicole
Wang, Yucai
Tam, Constantine
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew
Jain, Preteesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 108 - 109
[26] Efficacy of Pirtobrutinib in BTK-Inhibitor Pre-treated Relapsed/ Refractory CLL/SLL: Phase 1/2 BRUIN Study Results by Prior BCL2-Inhibitor Therapy
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Roeker, Lindsey E.
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John
Shah, Nirav N.
Ujjani, Chaitra
Fahkri, Bita
Coombs, Catherine C.
Flinn, Ian
Patel, Manisha R.
Nasta, Sunita D.
Cohen, Jonathon B.
Alencar, Alvaro J.
Cheah, Chan Y.
Ma, Shuo
Rhoades, Joanna M.
Jagadeesh, Deepa
Zinzani, Pier Luigi
Osterborg, Anders
Izutsu, Koji
Tsai, Donald E.
Abada, Paolo
Balbas, Minna
Ruppert, Amy S.
Li, Jian
Jurczak, Wojciech
Wierda, William G.
Stilgenbauer, Stephan
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 119
[27] Efficacy of Pirtobrutinib in Relapsed/ Refractory CLL and Richter Transformation: Additional Results From the Phase 1/2 BRUIN Study
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 16 - 16
[28] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo B.
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BLOOD, 2022, 140 : 2316 - 2320
[29] Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study
Eyre, Toby
Pagel, John M.
Coombs, Catherine C.
Shah, Nirav N.
Lamanna, Nicole
Lech-Maranda, Ewa
Woyach, Jennifer
Wierda, William G.
Cheah, Chan Y.
Roeker, Lindsey
Patel, Manish R.
Fakhri, Bita
Barve, Minal A.
Tam, Constantine S.
Lewis, David
Gerson, James N.
Alencar, Alvaro
Taylor, Justin
Abedel-Wahab, Omar
Ghia, Paolo
Schuster, Stephen J.
Chen, Jessica
Nair, Binoj
Tsai, Donald E.
Ku, Nora C.
Davids, Matthew S.
Brown, Jennifer R.
Jurczak, Wojciech
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 37 - 38
[30] Pirtobrutinib: First Non-covalent Tyrosine Kinase Inhibitor for Treating Relapsed or Refractory Mantle Cell Lymphoma in Adults
De, Surya K.
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (30) : 4757 - 4762

← 1 2 3 4 5 →